Lingrei Pharmaceutical: Magaldrate Chewable Tablets Receive Drug Registration Certificate

2026-03-25 00:16:53

People’s Financial News, March 23 — Lingrui Pharmaceutical (600285) announced on March 23 that it recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration for aluminum magnesium carbonate chewable tablets. Aluminum magnesium carbonate chewable tablets are over-the-counter medicines for acid relief and gastric mucosal protection. According to relevant national policies, these aluminum magnesium carbonate chewable tablets are approved for production as chemical drug Category 4, which is considered equivalent to passing the consistency evaluation of generic drug quality and efficacy. It is expected to have a positive impact on the company’s operations.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.